Genmab reports share buy-back transactions

Genmab (CSE:GMAB) A/S (NASDAQ:GMAB), a leading biotechnology company specializing in antibody therapeutics for the treatment of cancer, announced today its latest transactions under its current share buy-back program as part of its capital allocation strategy.

The transactions took place between May 5 and May 9, 2025, as detailed in the appendix of the company’s recent Form 6-K filing with the U.S. Securities and Exchange Commission (SEC). This report is intended to provide transparency regarding the company’s return of value to shareholders and is in accordance with the European Market Abuse Regulation.

The share buy-back program, initially announced by Genmab, is executed under the authorization granted by the company’s shareholders. The purpose of the program is to adjust the capital structure of the company by returning funds to shareholders and to meet obligations arising from share-based incentive programs for employees.

As per the latest filing, the company has repurchased shares within the specified timeframe, the details of which are provided in the appendix of the filing. The transactions have been carried out under the program set up and managed by a third-party financial institution, which makes trading decisions independently of and without influence by Genmab with regards to the timing of the purchases.

Genmab’s ongoing commitment to share buy-backs reflects the company’s stable financial position and confidence in its long-term value creation for shareholders. The buy-back program is an integral component of Genmab’s broader capital distribution policy, which also includes potential dividend payments.

The company’s executive management remains focused on executing its strategy and delivering on its pipeline of innovative cancer treatments. Genmab’s financial strength enables it to continue investing in its research and development activities while also providing returns to its investors.

The details of the share buy-back transactions are to be incorporated by reference into Genmab’s registration statements on Form S-8 and will be a part thereof from the date of the filing, to the extent they are not superseded by subsequent documents or reports filed or furnished.

Investors and stakeholders can access the full report on the SEC’s website, which includes the specific number of shares repurchased and the transaction prices. This disclosure is based on a press release statement and provides a factual summary of the company’s recent financial activities as it pertains to its share buy-back program.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.